Scientific Program

Conference Series Ltd invites all the participants across the globe to attend Annual Congress on Medicine Bangkok, Thailand.

Day 2 :

Conference Series World Medicine 2018 International Conference Keynote Speaker Elka Touitou  photo
Biography:

Elka Touitou is an internationally recognized authority in the field of drug delivery and design of new carrier technologies for efficient nasal, transdermal and cannabinoid new products. She has pioneered leading technologies in the field that evolved into startup companies. Also she has been invited as a Visiting Professor at Universities in Europe and Asia. She has been the instructor of numerous graduate students. She has broad experience in collaborating with the pharmaceutical industry serving in their advisory board. She has more than 100 scientific publications including original research, reviews, book chapters and coeditor of two books. She is the inventor of international granted patents.
 

Abstract:

Treatment of Central nervous system (CNS) diseases could be improved by efficient delivery of the therapeutic agents to brain. Nasal drug administration is one promising strategy. However, direct delivery to brain with no need of a special device is a challenging task, many molecules being poorly absorbed through the nasal mucosa. The presentation will review work showing improved treatment by enhanced delivery to brain of drugs, tested in animal models for various diseases. Systems were designed by means of novel nanovesicular carriers for nasal administration of central acting drugs. Delivery to brain was tested by imaging technologies and quantification of drug levels in brain and plasma. Treatments and pharmacodynamic effects were evaluated in animal models for MS, pain, insomnia, Parkinson’s disease and hot flushes. Results of several studies showed effective delivery of various drugs to brain and indicated the efficiency of the treatments. It presents near infrared images of the brain indicating superior accumulation of a model molecule in the organ, ten minutes following nanovesicular system nasal administration, relative to controls. An interesting finding is the statistically significant decrease of clinical scores and inflammatory cytokine expression in Experimental Autoimmune Encephalomyelitis (EAE) mice following the nasal administration of Glatiramer Acetate (GA) and Cannabidiol (CBD) combination. Moreover, neuron regeneration was observed in the hippocampus of this animal model. The enhanced delivery to brain and efficient pharmacodynamic effects achieved by administration of nasal nanovesicular systems could open a new way for non-invasive delivery to brain and improved treatment of CNS diseases. 

Keynote Forum

Michael Har-Noy

Immunovative Therapies Ltd., Israel

Keynote: New generation of therapeutic cancer vaccines affordable to the masses

Time : 10:15-11:00

Conference Series World Medicine 2018 International Conference Keynote Speaker Michael Har-Noy  photo
Biography:

Michael Har-Noy is an Immunologist and Bioengineer with over 30 years of experience in cellular immunotherapy, having developed and clinically tested unique LAK, TIL and Th1 cell therapies for cancer and HIV/AIDS as well as methods for their manufacturing under GMP. He has attended an MD-PhD program at Rush University Medical School in Chicago specializing in Immunology and Bioengineering and performed Postdoctoral work at the University of Minnesota. He did a Clinical Research Fellowship in Immunology and AIDS at Harvard University Medical School where he was appointed as an Officer. He is currently affiliated with the Department of Bone Marrow Transplantation and Cancer Immunotherapy at the Hadassah-Hebrew University Medical Center in Jerusalem. He is also the Founder and CEO of Immunovative Therapies, Ltd. He has over 200 issued patents in the field of immunotherapy and is an expert in the design and development of process control algorithms for large-scale, high density cell culture bioreactors. His passion is to develop effective, minimally toxic cancer vaccines that can be economically mass produced and distributed so that they can be affordable to patients suffering from advanced cancer in economically disadvantaged regions.
 

Abstract:

Immunotherapy is now accepted as a new treatment modality for cancer. US FDA approved checkpoint blockage, anti-CTLA4 and anti-PD1/L1, monoclonal antibody drugs and autologous CAR-T cells are the first generation of drugs with an immunemediated anti-tumor mechanism. These immunotherapy drugs have demonstrated ability to control metastatic disease and hematological malignancies. However, these first generation immunotherapy drugs work in only a limited number of indications and in only a minority subset of patients within these limited indications, particularly the small subset with tumors that express high mutational load status. In addition, these first generation drugs have unique and often serious immune-related sideeffects that require intensive expert supportive care. While many patients can achieve long-term disease control with current immunotherapy drugs, the majority of patients experience only the side-effects without clinical benefit. The limited applicability and efficacy of checkpoint blockade drugs is due to the requirement for a pre-existing, effective immune response to be resident within the tumor lesions (“hot” tumors) in order for the mechanism of checkpoint blockade to be effective. The majority of human tumors lack an effective immune cell infiltrate (“cold” tumors). CAR-T cells are directed against surface antigens on tumor cells. This limits the use of this technology to hematological malignancies, as solid tumors lack unique surface antigen targets which are not expressed on normal tissues. Additionally, due to the cost of current immunotherapy drugs and the cost to treat the side-effects, the majority of the population in the developing world is unable to afford these drugs. Accordingly, there is a high unmet medical need for a broadly effective, low toxicity cancer immunotherapy drug that could be afforded by economically disadvantaged cancer patients. The immunotherapy drugs with the greatest potential for broad applicability against all types of tumors is the subclass of therapeutic cancer vaccines. This type of immunotherapy approach is designed to educate the immune system to specifically recognize tumors and thus create “hot” tumors as well as support the development of immune memory which provides long-term protection against recurrence of the targeted tumor without need for further treatment. Unfortunately, therapeutic cancer vaccines alone or in combination with checkpoint blockade have had disappointing results in the clinic. The failure of therapeutic vaccines is attributed to the multiplicity of complex immunosuppressive and immunoavoidance mechanisms employed by tumors to evade immune elimination. We have developed a new generation of therapeutic vaccines that are designed to provide non-toxic tumor debulking immunity and disease stabilization that are available in an “off-the-shelf” format that potentially can make these vaccines “affordable to the masses”. This new generation therapeutic vaccine technology is based upon the proven Graft-versus-tumor (GVT) mechanism that occurs after allogeneic, non-myeloablative stem cell transplantation (ASCT) procedures. GVT has been described as the most powerful anti-tumor mechanism ever discovered as it is the only mechanism proven capable of mediating tumor debulking of chemotherapyrefractory metastatic disease. However, the clinical application is limited due to the GVT effect association with the extremely toxic and often lethal side-effect known as Graft-versus-host disease (GVHD). The separation of the beneficial GVT effect from the devastating GVHD effects is the “holy grail” of transplant research. However, the intimate and proportional relationship of these effects has not allowed successful separation. We have developed a bioengineered allograft called “AlloStim®” which has been engineered to reverse the immunological flow of the linked GVT/GVHD effects to enable the effects to emanate from the host, rather than the draft. This creates a non-toxic Host-versus-graft (HVG) rejection that is linked to a Host-versustumor (HVT) effect. The HVT effect is as powerful as the GVT effect of ASCT, without need for chemotherapy conditioning or matched tissue donor. Because the AlloStim allograft is derived from healthy blood donors and one donor can produce enough cells after ex-vivo differentiation and expansion to treat potentially hundreds of patients, the drug provides an economy of scale that can be translated into a treatment affordable to the masses. We will be presenting clinical data demonstrating the anti-tumor effects of this next generation therapeutic vaccine in Thai patients with advanced/metastatic head and neck cancer and advanced/metastatic hepatocellular carcinoma. 

Break: Networking & Refreshments Break: 11:00-11:20 @ Foyer
  • Workshop
Location: Vivaldi (4th Floor)

Session Introduction

Gabriela Zaharia Rusu

Medical Nursing & Rehabilitation Center, Israel

Title: Cognitive behavioral therapy in an older patient with a specific phobia; dromophobia: Case report

Time : 11:20-12:10

Speaker
Biography:

Gabriela Zaharia Rusu is working as Chief Nurse in the Department for Rehabilitation Center, Israel. As a Health Coach, she uses a variety of health-promoting and evidence-based strategies to achieve growth, overall health and well-being of the patients, incorporating different aspects such as nutrition, stress and time management, chronic disease management and effective coping skills with each client, as well as providing comprehensive health assessments, conducting learning-style assessments to identify the best teaching methods for enhancing client understanding and empowerment.
 

Abstract:

This is a case report of a clinical case in which an older patient is presented motivation to modify dysfunctional avoidance behavior in order to be able to confront her phobia to cross the street. Older adult who has experienced a road accident developed fear to cross the street and is in the greater risk for physical and mental problems. Dromophobia is the fear of crossing streets; the term originated from Greek word dromo (race course) and phobia (fear). Phobias arise from the combination of external events such as traumatic events, roads accident and internal predispositions like heredity or genetics. Many specific phobias can be traced back to a specific triggering event, usually a traumatic experience at an early age. Symptoms of dromophobia vary by person depending on their level of fear. The symptoms typically include extreme anxiety, shortness of breath, rapid breathing, irregular heartbeat, sweating, nausea, dry mouth, nausea, inability to articulate words or sentences, dry mouth and shaking, muscular stiffness, avoidance to cross the street, refusal to go outside without a trusted companion (spouse) and social isolation. Cognitive Behavioral Therapy (CBT) was used to treat the patient. CBT method in dromophobia treatment was effective providing good results, improving the patient qualities of life. 

  • Sessions
Location: Vivaldi (4th Floor)

Session Introduction

Sung-Chen Tung

Sung-Ful Sexual Health Center, Taiwan

Title: Treatment of genito-pelvic pain/penetration disorder: From cognitive-behavioral sex therapist view

Time : 12:10-12:40

Speaker
Biography:

Sung-Chen Tung is a Cognitive-Behavioral Sex Therapist and a Writer for Intimate Relationships. As the President of Chung-Hua Sexual Health Promotion Association, she aims at promoting couple’s sexual  well-being and training sex therapists. She has expertise in treatment of psychogenic sexual dysfunction by CBT approach, especially on premature ejaculation, erectile dysfunction and female dyspareunia.
 

Abstract:

Background & Aim: Genito-Pelvic Pain/Penetration Disorder (GPPPD) is one of the leading causes of female sexual dysfunction but not well defined or understood and affects women’s sexual health and satisfaction. The purpose of this study were described the patients’ sexual behaviors before treatment and clinical experience of help-seeking for GPPPD, and compared effectiveness of intensive and weekly Cognitive Behavioral Therapy (CBT) on GPPPD. Methodology: 27 patients meeting DSM-5 criteria for GPPPD were enrolled. 14 patients from China who undertook intensive CBT (iCBT- three 1.5 hour sessions over three days) used a comparison group and 13 patients from Taiwan who undertook weekly CBT (wCBT- four 2 hour sessions over 4 weeks). All participants responded to sex history, Female Sexual Function Index (FSFI) and Sexual Anxiety Scale (SAS) before the first session and 3-month follow-up after intervention.
Result: The subjects were 31.2 years of age on average and 4.6 years of GPPPD duration. 74.1% were severe and 96.3% were lifelong GPPPD, 60.9% had non-penetrative sex and 29.6% seek for otherwise treated before for CBT intervention. At 3 months of follow up significant improvements found in lubrication (Z=-2.314, p=0.021), sexual satisfaction (Z=-2.694, p=.007), and sexual pain (-3.606, p<0.001). 25.9% had been defined normal female sexual function (FSFI>26.55) and 92.6% had intercourse in the last 1 month. iCBT had no significant reduce in SAS (p=0.374~0.953) and wCBT (p=0.005~0.196).
Conclusion: More than half of the females with GPPPD had non-penetrative sexual behaviors. iCBT and wCBT program had significant effectiveness on reducing sexual pain and improve sexual function in GPPPD. But iCBT cannot offer cognitive restructure enough to reduce sexual anxiety.
 

Speaker
Biography:

Naeem Mubarak is currently pursuing PhD and his research areas include qualitative research, systematic reviews, evidence-based research, pharmacoeconomics and clinical trials.
 

Abstract:

Objective: To evaluate the impact of collaborative practice between Community Pharmacist (CP) and General Physician (GP) in asthma management.
Methods: An extensive search was carried out in 10 databases (PubMed, Medline/Ovid, CINAHL, Scopus, Web of Science, Cochran central register of controlled trials, PsycARTICLES®, Science Direct, Education Resource Information Centre, PROQuest) and grey literature using selected MeSH and keywords such as community pharmacist, general physician, and medicine use review. After screening, 23 studies were used for evidence synthesis. The risk of bias was assessed by Cochrane risk of bias tool (EPOC). Studies were included only if there was a definite evidence of collaborative practice between CPs and GPs in management of asthma, such as CPs conducting medications reviews or providing education and counseling. The studies need to report at least one of the outcomes which include clinical, humanistic and economical. Results: A total of 23 studies (6 RCTs, 4 C-RCT, 3 controlled trials, 3 case control and 7 pre-post) were included for metaanalysis. The collaboration between CP and GP has shown consistently improvements in medication use, inhalation techniques, diseases knowledge, control of asthma, and quality of life However, clinical finding on lungs functions was not significantly improved. The collaboration was shown to be value for money, but the economic outcomes lacked RCT s designs and thus the evidence may not be considered as strong as it was for clinical and humanistic outcomes. Conclusion: The findings from this review established strong evidence in approval of the positive impact of collaborative practice between CP and GP in the management of asthma.
 

Break: Lunch Break: 13:10-14:10 @ Public Restaurant
Biography:

Nindya Permata Bunda Surya Utami is an undergraduate student of Faculty of Medicine, University of Indonesia (FMUI) who has high interest in doing research. She is dedicated toward her study and always eager to learn new things.
 

Abstract:

WHO states that Cardiovascular Disease (CVD) is the cause of 31% of deaths worldwide reaching 17.7 million deaths per year. Causes of CVD include smoking, unbalanced food intake, low physical activity and excessive alcohol consumption. The common pathophysiology of CVD is the formation of atherosclerotic plaques which begins with endothelial dysfunction that is closely related to Diabetes Mellitus (DM). Existing treatment focus on preventing the formation of atherosclerotic plaques by lowering blood cholesterol levels and blood viscosity thereby preventing the formation of shear strength that can damage the endothelial layer. Centella asiatica (CA) is a well-known herbs used as oxidative-stress remedy. Literature review was conducted to determine its potency in preventing CVD by searching two journal databases, PubMed and EBSCOhost. The search was carried out using Boolean Operator as follows: Cardiovascular AND therapy AND Centella asiatica. Sources are not year-limited and include animal studies, RCT reports or related reviews. Based on literature review, there are various studies linking the protective effect of CA on CVD. In vivo study conducted by Ramachandran, et al. showed that in mice with DM, lipid profiles of DM mice were given asiatic acid shifted towards normalcy which reduce the risk of atherosclerotic plaque formation. RCT studies conducted by Cesarone, et al. showed that in the group given CA therapy for 12 months, there was an increase in GSM parameters and an improvement in the texture of atherosclerotic plaques which showed the formation of stable with low risk for thrombus. RCT study conducted by Luzzi, et al. on high-oxidative stress asymptomatic patients given Pycnogenol and CA extract showed an increase in the stability of atherosclerotic plaque as indicated by an increase in plaque density, decrease in the number and size of plaques. These results indicate the potential of CA as a good preventive cardiovascular therapy.
 

Fahad Hussain

Noakhali Science and Technology University, Bangladesh

Title: Investigation of antioxidant potentials of Acacia nilotica, Ocimum sanctum and Alpinia nigra

Time : 14:40-15:10

Speaker
Biography:

Fahad Hussain is working as an Assistant Professor at Department of Pharmacy in Noakhali Science and Technology University, Bangladesh. He is also working as the Editor of few health and pharmacy related publications.
 

Abstract:

Acacia nilotica, Ocimum sanctum and Alpinia nigra are used traditionally in different ailments in rural settings of Bangladesh. These medicinal plants were studied for their total phenolic and total flavonoid contents as a partial approach to rationalize the use of them. Antioxidant activity was also determined measuring ferric reducing power assay and 1, 1’-Diphenyl-1Picrylhydrazyl radical (DPPH) scavenging activity. A. nilotica showed highest total phenolic content while O. sanctum showed highest flavonoid contents among the studied three plants. Similarly, IC50 values of the extracts of A. nilotica, O. sanctum and A. nigra against DPPH were 39.62, 48.81, 70.85 µg/ml, respectively. The reducing power of the extract was found to be concentration dependent and O. sanctum showed highest reducing power followed by A. nilotica. The reducing power of these two plants was fairly close to positive control ascorbic acid. Further studies are suggested such as in vivo testing and elucidation of mechanism of action of inherited bioactive compounds to support its folkloric use in the treatment of diseases.
 

Speaker
Biography:

Aisyah Aminy Maulidina is currently pursuing a General Practitioner degree in Faculty of Medicine, University of Indonesia. Her interest in research is cultivated through a research module.
 

Abstract:

High-fructose and cholesterol diet nowadays has increased the incidence of obesity, dyslipidemia, insulin resistance, and metabolic syndrome which are the main risk factors of Non-Fatty Pancreas Disease (NAFPD), a pancreatic disease that may lead to pancreatic cancer. The pathogenesis and treatment of NAFPD is currently not well understood yet, but studies show that NAFPD is a reversible state which can be treated by modifying its underlying risk factors. The use of simvastatin in managing pancreatic disease, although was shown to reduce cancer risk and increase survival of patients with pancreatic cancer, raises concerns as simvastatin was recently found to induce diabetes and worsen hyperglycemia and A1c levels in pre-existing diabetes. A. indica Linn. is known to have flavonoids and polyphenols which may decrease serum LDL level and increase serum HDL level. A. indica Linn may also, in contrast to simvastatin, control post-prandial hyperglycemia. A study on mice induced with high fructose and a high cholesterol diet shows that A. indica Linn., with or without combination of simvastatin, helped reverse fatty formation in the pancreas. This article reviews the potential use of Acalypha indica Linn. extract as an alternative approach to modify the risk factors underlying NAFPD.
 

Break: Networking and Refreshments Break: 15:40-16:00 @ Foyer